Logo image
Back
What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study
Journal article   Open access   Peer reviewed

What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study

Bunja J Rungruang, Austin Miller, Thomas C Krivak, Neil S Horowitz, Noah Rodriguez, Chad A Hamilton, Floor J Backes, Linda F Carson, Michael Friedlander, David G Mutch, …
Cancer, v 123(6), pp 985-993
15 May 2017
DOI: https://doi.org/10.1002/cncr.30414
PMID: 27864921
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://europepmc.org/articles/pmc5339038View
Accepted (AM) Open Open Access (License Unspecified)

Abstract

Adult Aged Aged, 80 and over Carcinoma, Ovarian Epithelial Cytoreduction Surgical Procedures Female Humans Lymph Nodes - pathology Middle Aged Neoplasm Grading Neoplasm Metastasis Neoplasm Staging Neoplasms, Glandular and Epithelial - mortality Neoplasms, Glandular and Epithelial - pathology Neoplasms, Glandular and Epithelial - surgery Odds Ratio Ovarian Neoplasms - mortality Ovarian Neoplasms - pathology Ovarian Neoplasms - surgery Retroperitoneal Space - surgery Survival Analysis Treatment Outcome
The purpose of this study was to determine the effect of retroperitoneal (RP) exploration on progression-free survival (PFS) and overall survival (OS) in epithelial ovarian cancer (EOC) patients with stage IIIC disease who underwent optimal debulking surgery. Data were collected from records of the Gynecologic Oncology Group 182 (GOG-182) study of stage IIIC EOC patients cytoreduced to no gross residual disease (R0) or minimal gross residual (<1 cm) disease (MGRD) at primary surgery. Patients with stage IIIC disease by intraperitoneal (IP) tumor were included and divided into 3 groups: 1) > 2 cm IP tumor without lymph node involvement (IP/RP-), 2) > 2 cm IP tumor with lymph node involvement (IP/RP+), and 3) > 2 cm IP tumor with no RP exploration (IP/RP?). The effects of disease distribution and RP exploration on PFS and OS were assessed using Kaplan-Meier and proportional hazards methods. There were 1871 stage IIIC patients in GOG-182 who underwent optimal primary debulking surgery. Of these, 689 (36.8%) underwent RP exploration with removal of lymph nodes from at least 1 para-aortic site, and 1182 (63.2%) did not. There were 269 patients in the IP/RP- group, 420 patients in the IP/RP + group, and 1182 patients in the IP/RP? group. Improved PFS (18.5 vs 16.0 months; P < .0001) and OS (53.3 vs 42.8 months; P < .0001) were associated with RP exploration versus no exploration. Patients with MGRD had improved PFS (16.8 vs 15.1 months, P = 0.0108) and OS (44.9 vs 40.5 months, P = 0.0076) versus no exploration. RP exploration at the time of primary surgery in patients with optimally debulked stage IIIC EOC is associated with a survival benefit. Cancer 2017;123:985-93. © 2016 American Cancer Society.

Metrics

8 Record Views
9 citations in Web of Science
10 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being
#5 Gender Equality

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Oncology
Logo image